Allogene Therapeutics’ CAR-T therapy removed all remaining detectable lymphoma cells in just over half of treated patients, according to an early look at the Phase

Plus, news about AbbVie, SynOx, Eli Lilly’s Jaypirca, ImageneBio, Nxera Pharma, Neurocrine and Novartis: Neomorph raises $100M more for molecular glues: San Diego-based Neomorph has

Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumor therapies as well as diagnostic agents

Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.